Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. (Symbol: BEAT) is a cutting-edge medical technology company that focuses on developing and commercializing high-resolution ambulatory Electrocardiogram (ECG) solutions. These solutions are designed to detect and monitor cardiac diseases outside traditional healthcare settings, providing critical diagnostic capabilities in a more accessible manner.
HeartBeam's flagship product is an innovative, credit card-sized ECG device that is diagnostically equivalent to a cardiologist reading a patient's 12-lead ECG and examining the patient. This compact device integrates seamlessly with a cloud-based diagnostic expert system, offering a comprehensive and user-friendly solution for cardiac monitoring.
Notably, studies designed by Harvard Medical School faculty have demonstrated that HeartBeam's technology performs on par with, or better than, world-class cardiologists in diagnosing heart attacks. The system features personalized diagnostic thresholds and unique ECG markers that help pinpoint the location of a heart attack on a 3D heart model, enhancing the accuracy and depth of diagnostic information provided to healthcare professionals.
One of the key components of HeartBeam's technology is the iCardiologist application, which uses artificial intelligence and machine learning to continually improve its diagnostic accuracy and predictive capabilities. This application aids cardiologists by providing detailed patient analysis, thereby supporting more informed and timely medical decisions.
HeartBeam has developed a proprietary and patented Vector Electrocardiography (VECG) technology platform, which is the cornerstone of its high-resolution ECG solutions. The company has validated this platform and is in the process of seeking U.S. Food and Drug Administration (FDA) clearance for its initial telehealth products.
With its innovative approach and proven technology, HeartBeam is poised to make significant strides in the field of cardiac care, offering practical solutions that can be utilized outside traditional healthcare environments, thereby broadening access to critical diagnostic tools and improving patient outcomes.
Latest News: Source: HeartBeam, Inc.
- ------
- ------
- ------
HeartBeam, Inc. (NASDAQ: BEAT), a leader in cardiac technology, will hold a conference call on November 10, 2022, at 4:30 p.m. Eastern time to discuss its Q3 results for the period ending September 30, 2022. CEO Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will lead the call, reviewing recent announcements and future milestones. A press release detailing results will precede the call. Investors can access the call via dial-in or webcast, and a replay will be available until February 10, 2023.
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology firm, will present at the LD Micro Main Event XV Conference in Los Angeles from October 25-27, 2022. CEO Branislav Vajdic, PhD, will lead in-person meetings and a presentation on October 25 at 4:30 pm PT in TRACK 3. The conference highlights HeartBeam's unique 3D-vector ECG technology for heart attack detection. The presentation can be streamed live or viewed later on their investor relations site. More details on registration and the conference can be found online.
HeartBeam, Inc. (NASDAQ: BEAT) announced the appointment of Dr. Peter J. Fitzgerald as Chief Medical Officer. Dr. Fitzgerald, a leader in interventional cardiology, brings extensive clinical experience and expertise in developing industry collaborations. He aims to enhance clinical strategies and partnerships for advancing HeartBeam's novel diagnostic tools, including the 3D-vector ECG platform designed for heart attack detection. HeartBeam's innovative products, AIMI™ and AIMIGo™, are currently pending FDA clearance, with potential to significantly improve patient outcomes.
HeartBeam, Inc. (NASDAQ: BEAT) has announced the expansion of its product portfolio to address the multibillion-dollar atrial arrhythmia detection market. New developments include the HeartBeam AIMIGo™ 3L device, designed to record 3D cardiac activity and facilitate clinician reviews with a planned FDA submission in Q4 2022. Future versions will add smartwatch connectivity and enhanced atrial fibrillation detection. The company is also ensuring component procurement for device production to mitigate supply chain issues, pushing towards comprehensive cardiac care anytime, anywhere.
HeartBeam, Inc. (NASDAQ: BEAT) will present at the Dawson James Small Cap Growth Conference on
HeartBeam, Inc. (NASDAQ: BEAT) announced the issuance of a patent for its AIMIGo™ device, enabling a synthesized 12-lead ECG outside medical settings. This innovation allows patients to send heart signal data directly to physicians, enhancing heart attack detection. With around 18 million individuals in the US at risk for heart attacks, the technology addresses a significant healthcare need. HeartBeam's AIMIGo is the only wallet-sized 12-lead ECG solution, aiming to reduce emergency visits and expedite care while improving patient quality of life.
HeartBeam, Inc. (NASDAQ: BEAT) announced a virtual roadshow webinar set for
HeartBeam, Inc. (NASDAQ: BEAT) has received a patent for its innovative 12-lead ECG patch monitor, which allows for the detection of acute coronary syndrome and cardiac arrhythmia outside medical settings. This technology enhances traditional ECG diagnostics, contributing to a projected global market of
HeartBeam, Inc. (NASDAQ: BEAT) has announced a virtual roadshow webinar on September 20, 2022, at 4:30 p.m. ET. During this event, a new video showcasing the HeartBeam AIMIGo technology for heart attack detection will be unveiled. While the AIMI and AIMIGo technologies are pending FDA clearance, they aim to enhance heart attack detection outside of medical settings. The webinar will feature CEO Branislav Vajdic and other executives discussing the company’s milestones and 510(k) application progress. Access the webinar via the provided link.
HeartBeam, Inc. (NASDAQ: BEAT) has submitted a 510(k) application to the US FDA for its HeartBeam AIMI™ technology, aimed at improving heart attack diagnosis. This step is crucial for the company's commercialization efforts within a
FAQ
What is the current stock price of Heartbeam (BEAT)?
What is the market cap of Heartbeam (BEAT)?
What does HeartBeam, Inc. do?
What is unique about HeartBeam's technology?
How does HeartBeam's iCardiologist application work?
What is VECG technology?
Has HeartBeam's technology been validated?
Is HeartBeam seeking FDA clearance?
What are the benefits of HeartBeam's ECG solutions?
Can HeartBeam's technology locate a heart attack?
How is HeartBeam improving cardiac care?
Where can I find the latest news on HeartBeam, Inc.?
